You just read:

Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)

News provided by

Theravance Biopharma, Inc.

Jul 19, 2017, 16:25 ET